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Abstract 
Under conditions of genotoxic stress, cancer cells strongly rely on efficient DNA 
repair to survive and proliferate. The human BRCA2 tumor suppressor protein is 
indispensable for the repair of DNA double-strand breaks by homologous 
recombination (HR) by virtue of its ability to promote RAD51 loading onto single-
stranded DNA. Therefore, blocking the interaction between BRCA2 and RAD51 
could significantly improve the efficacy of conventional anti-cancer therapies. 
However, targeting protein-protein interaction (PPI) interfaces has proven challenging 
because flat and large PPI surfaces generally do not support binding of small 
molecule inhibitors. In contrast, peptides are more potent for targeting PPIs but are 
otherwise difficult to deliver into cells. Here, we report that a synthetic 16-mer 
peptide derived from the BRC4 repeat motif of BRCA2 is capable of blocking 
RAD51 binding to BRCA2. Efficient non-cytotoxic cellular uptake of a nona-arginine 
(R9)-conjugated version of the BRC4 peptide interferes with DNA damage-induced 
RAD51 foci formation and HR. Moreover, transduction of the BRC4 peptide impairs 
replication fork protective function of BRCA2 and triggers MRE11-dependent 
degradation of nascent DNA in response to DNA replication stress. Finally, the BRC4 
cell-penetrating peptide (CPP) confers selective hypersensitivity to PARP inhibition 
in cancer cells but spares non-cancerous cells. Taken together, our data highlight an 
innovative approach to develop novel peptide-based DNA repair inhibitors and 
establish BRCA2-derived CPPs as promising anti-cancer agents. 
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Introduction 
Double-strand breaks (DSBs) are highly detrimental DNA lesions because, if left 
unrepaired or misrepaired, they can trigger cell death and genomic instability, 
ultimately causing cancer (1). To circumvent this threat, cells are equipped with 
diverse DSB repair mechanisms including non-homologous end-joining (NHEJ) and 
homologous recombination (HR) as the two major pathways (2). Furthermore, recent 
work has established that in response to DNA replication stress several key HR 
factors play a crucial role in protecting stalled DNA replication forks from nucleolytic 
degradation (3). Because rapidly dividing cancer cells rely on efficient DSB repair 
and fork protection mechanisms for their survival, inhibiting HR represents an 
attractive strategy for the development of novel therapeutic drugs, in particular when 
used in combination with DNA-damaging agents (4,5). 
The human BRCA2 protein plays an essential role in HR by promoting homology 
search and stimulating strand invasion into the sister chromatid (6). Specifically, 
following DNA-end resection, BRCA2 directs RAD51 filament nucleation onto RPA-
coated single-stranded DNA (ssDNA) (7). RAD51 interacts with two distinct regions 
in BRCA2, the BRC repeat motifs and a C-terminal domain (8-10). Importantly, the 
eight evolutionarily conserved BRC repeats, each consisting of about 35 amino acids, 
significantly differ in their capacity to bind RAD51 with BRC4 displaying the highest 
affinity (11,12). Consequently, it was proposed that BRC repeats 1-4 facilitate 
nucleation of RAD51 by binding monomeric RAD51 and reducing its ATPase 
activity (11,13). Structural analysis of the BRC4 repeat identified residues 1523-
GFHTASG-1529 of BRCA2 to structurally mimic the self-oligomerization motif of 
RAD51 (14). In addition to the FHTA motif, a second consensus tetrameric module in 
BRC4, denoted as LFDE motif, was shown to bind to a distinct pocket in RAD51 
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distant from the oligomerization interface (15). In contrast to the BRC repeats, the C-
terminal domain does not bind monomeric RAD51 but instead stabilizes RAD51 
nucleoprotein filaments (9,10). Taken together, compounds that selectively and 
efficiently block BRCA2-RAD51 interaction could advance into the clinic as bona 
fide HR inhibitors for both monotherapy and add-on therapy with DNA-damaging 
agents. 
The physical nature of protein-protein interaction (PPI) interfaces often renders them 
unable to support binding of small molecule inhibitors (SMIs). Instead, peptide 
therapeutics offer an alternative way to target PPIs with key advantages over SMIs, 
including their direct similarity to protein fragments and the coverage of extensive 
PPI interfaces (16). However, poor membrane permeability has previously limited 
their use to extracellular targets (17). Thus, hydrophilic peptides are reliant on a 
permeation enhancing strategy that facilitates targeting of intracellular molecules 
(18). Recently, cell-penetrating peptides (CPPs) have been developed to enhance the 
cellular uptake and nuclear translocation of membrane-impermeable cargo molecules 
(19). They comprise a highly diverse class of short, primarily cationic peptides that 
combine a limited cytotoxicity and the ability to mediate receptor-independent 
transport of cargoes across cell membranes (20). Notably, the nona-arginine (R9) 
peptide is one of the most potent CPPs, giving a high transduction efficiency 
combined with low cytotoxicity (21). 
Here, we design a cell-penetrating peptide comprised of a 16 amino-acid stretch of the 
BRCA2 BRC4 repeat able to inhibit BRCA2-RAD51 interaction. Our detailed 
functional analysis reveals that an R9-fused BRC4 CPP prevents RAD51 loading onto 
ssDNA, resulting in defective homology-mediated repair of DSBs as well as 
increased MRE11-dependent degradation of stalled DNA replication forks. 
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Consequently, peptide incubation renders cells hypersensitive to the PARP inhibitor 
olaparib, providing a potential use for BRCA2-derived peptides in the treatment of 
certain types of cancer. 
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Materials and Methods 
Cell culture 
HeLa, U2OS, RPE1, MRC5 (all from ATCC) and HeLa DR-GFP were cultured in 
Dulbecco's Modified Eagle Medium (DMEM, Gibco) supplemented with 10% Fetal 
Calf Serum (FCS, Sigma-Aldrich), 100 U/ml penicillin and 100 µg/ml streptomycin 
(P/S, Life Technologies). PEO1 and PEO4 cells were purchased from the Health 
Protection Agency Culture Collections (Salisbury, UK) and cultured in RPMI 
Medium (Gibco) supplemented with 10% FCS, 2 mM sodium pyruvate (Gibco) and 
P/S. MCF10A cells were purchase from American Type Culture Collection (ATCC, 
Manassas, VA) and cultured in DMEM/F12 (Gibco) containing 5% Horse Serum 
(Gibco), 20 ng/ml human EGF (Sigma-Aldrich), 0.5 mg/ml Hydrocortisone (Sigma-
Aldrich), 10 μg/ml Insulin and P/S. Stable U2OS cells expressing GFP-RAD51 (22) 
were grown in DMEM supplemented with 10% Tet-system approved FCS (Sigma-
Aldrich) and P/S. To induce GFP-RAD51 expression, cells were treated with 1 μg/ml 
doxycycline (Dox, Sigma Aldrich) for 24 hours. All cell lines were confirmed to be 
free of mycoplasma contamination on a regular basis (PCR Mycoplasma Test Kit, 
AppliChem). Cells were passaged for no longer than 2 months after thawing of early-
passage stocks. For cells that have been received from secondary sources no cell line 
authentication was performed. Irradiation was performed using a Faxitron X-ray 
machine. 
 
Chemicals and peptides 
Camptothecin (CPT), RAD51 inhibitor B02 (23), cycloheximide, hydroxyurea (HU) 
and mirin (24) were purchased from Sigma-Aldrich. Olaparib (AZD2281) was 
provided by Selleck Chemicals. Thymidine analogs CIdU, IdU and EdU were 
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purchased from Sigma-Aldrich and Life Technologies, respectively. Custom-designed 
peptides were purchased from Bachem AG (Bubendorf, Switzerland) and, if not 
specified, synthesized according to standard practice (L-amino acids, N-terminal tag 
or acetylation, C-terminal amidation). Lyophilized peptides were dissolved in PBS at 
1 mg/ml. 
 
Antibodies 
A detailed list of all primary and secondary antibodies can be found in Supplementary 
Tables 1 and 2, respectively. 
 
siRNA 
A detailed list of siRNA oligonucleotide sequences used in this study can be found in 
Supplementary Table 3. siRNA oligos were used at a final concentration of 10 nM 
and transfected using Lipofectamine RNAiMAX (Invitrogen) according to 
manufacturer's instructions. 
 
Recombinant protein expression 
BRCA2 GST-fusion plasmids (GST-BRC 1-2, GST-BRC3-5, GST-BRC6-8, GST-C-
term) have been described before (25). BRCA2 GST-fusion proteins were expressed 
in BL21-CodonPlus-RIL E. coli by growing them overnight at 18°C using 100 μM 
isopropyl β-D-thiogalactoside. Recombinant full-length RAD51 was prepared as 
previously described (26). 
 
Immunoblotting 
If not specified otherwise, cells were lysed in Laemmli buffer (4% SDS, 20% 
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glycerol, 120 mM Tris-HCl pH 6.8) and resolved by Tris-glycine SDS-PAGE. In 
order to probe for BRCA2, 3-6% NuPAGE Tris-Acetate gels (ThermoFisher) were 
run according to manufacture's instructions. After transfer to nitrocellulose 
membranes, immunoblotting was performed with indicated primary antibodies 
overnight at 4°C and secondary antibodies for 1 hour at room temperature. Stained 
proteins were visualized using the Advansta WesternBright ECL reagent and the 
VilberLourmat Fusion Solo S imaging system.  
 
Pull-down assays 
For peptide pull-downs, 30 μl streptavidin-coupled Dynabeads (Life Technologies) 
were incubated with 5 μg (2.7 nmol) of biotinylated BRC4 peptides or biotin 
analogue d-Desthiobiotin (Sigma-Aldrich) in 1 ml PBS-T (0.1% Triton X-100) for 1 
hour at 4°C. Beads were washed three times with PBS-T and blocked for 30 min with 
0.3% BSA in PBS at 4°C. 50 ng (1.35 pmol) recombinant RAD51 together with 2 μM 
ATP was added to the beads and incubated for 2 hours in 700 µl PBS-T. The beads 
were washed four times with NTEN300 (20 mM Tris pH 7.4, 0.1 mM EDTA, 300 
mM NaCl, 0.5% NP-40) and once with TEN100 (20 mM Tris pH 7.4, 0.1 mM EDTA, 
100 mM NaCl) before complexes were boiled in 5x SDS sample buffer (25 mM Tris 
pH 6.8, 50% glycerol, 8% SDS, 500 mM DTT, 0.1% Bromphenol blue) and subjected 
to immunoblotting. For GST pull-down assays, glutathione sepharose beads (GE 
Healthcare) were incubated for 1 hour at 4°C with equalized amounts of BL21 E. coli 
soluble extracts expressing one of the four GST-BRCA2 fusion constructs in 
TEN100. Beads were washed three times with NTEN300 buffer and once with 
TEN100 before adding either 1 mg HeLa nuclear extracts (CilBiotech, Mons, 
Belgium) or 50 ng purified RAD51 supplemented with varying amounts of BRC4wt or 
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BRC4mut peptides filled up to 1 ml with TEN100. After 2 hours of incubation, beads 
were washed twice with NTEN500 (20 mM Tris pH 7.4, 0.1 mM EDTA, 500 mM 
NaCl, 0.5% NP-40), twice with NTEN300 and twice with TEN100 buffer before 
boiling in SDS sample buffer and protein analysis by immunoblotting. 
 
Co-immunoprecipitation 
Cell extracts were prepared using NP-40 extraction buffer (50 mM Tris-HCl pH 7.5, 
120 mM NaCl, 1 mM EDTA, 6 mM EGTA, 15 mM sodium pyrophosphate and 1% 
NP-40 supplemented with phosphatase inhibitors (20 mM NaF, 1 mM sodium 
orthovanadate) and protease inhibitors (1 mM benzamidine and 0.1 mM PMSF)). 
After Benzonase (Novagen) digestion for 30 min at 4°C, cell extracts were cleared by 
centrifugation. 2 mg of lysates were supplemented with increasing amounts of 
peptides filled up to 1 ml with NP-40 extraction buffer and incubated for 1 hour at 
4°C before adding 20 μl GFP-Trap agarose beads (ChromoTek) for 1 hour at 4°C. 
Beads were subsequently washed three times with GFP-IP buffer (100 mM NaCl, 
0.2% NP-40, 1 mM MgCl2, 10% glycerol, 5 mM NaF, 50 mM Tris-HCl pH 7.5) and 
boiled in SDS sample buffer for analysis by immunoblotting. 
 
Peptide transfection 
Cells were seeded either into 8-well chamber imaging slides (μ-Slide 8 Well, ibidi), 
24-well plates, 6-well plates, or 6 cm culture dishes (Sarstedt) and grown to around 
80% confluence at day of peptide transfection. Cells were washed at least once with 
PBS to remove residual FCS and incubated with indicated peptide concentrations in 
appropriate serum-free medium for 1 hour at 37°C. If not specified otherwise, the 
following incubation volumes were used: 0.3 ml for eight-well chamber imaging 
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slides and 24-well plates, 0.5 ml for 12-well plates and 2 ml for 6-well plates and 6 
cm culture dishes. 
 
Confocal microscopy 
40'000 cells were seeded into eight-well chamber imaging slides and grown 
overnight. After a 30 minutes staining with 0.5 μg/ml Hoechst 33342 (Life 
Technologies), cells were washed twice with PBS and incubated with indicated 
peptide concentrations. Cells were washed twice with PBS and imaged in Live Cell 
Imaging solution (ThermoFisher). Images were taken with CLSM SP5 Mid UV-VIS 
Leica with 63x objective at 37°C at ambient CO2 concentrations. 
 
Flow cytometry 
EdU incorporation was analyzed using the Click-it EdU technology (ThermoFisher) 
according to manufacturer's instructions. For peptide uptake studies, 100'000 cells 
were seeded into 12-well plates. The day after, peptide transfection was performed 
and cells were harvested by trypsinization to remove membrane-bound peptides. After 
one wash with PBS, cells were resuspended in PBS and subjected to flow cytometry 
analysis. To quantify intracellular peptide stability, same cells were released for 
indicated time points in DMEM + 10% FCS and fixed with 4% formaldeyhde (w/v) in 
PBS for 15 minutes at room temperature. To measure the TAMRA fluorescence 
intensity, the LSR II Fortessa equipped with a 561 nm laser line and a 586/15 band-
pass filter was used. Of note, the fluorescence intensity of TAMRA-labeled R9-
BRC4mut peptides was corrected for quenching by multiplying measured TAMRA 
intensity with a quenching factor. The quenching factor was calculated by loading 10 
pmol of freshly solubilized peptides on Tricine SDS-PAGE gel and quantifying 
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TAMRA intensity (see Figure 2C, lane 5). Fluorescein intensity was measured with 
Attune Nxt Flow Cytometer equipped with 488 laser and 530/30 band-pass filter. For 
each condition 20'000 events were recorded. MACS Quant® Calibration Beads 
(MACS Miltenyi Biotec) were applied for voltage standardization in order to exclude 
any machine-dependent variations between measurements.  
 
Tricine SDS-PAGE 
To resolve low molecular weight peptides, Tricine SDS-PAGE was performed as 
described previously (27). For peptide separation, Laemmli lysates were loaded onto 
16% Tricine SDS-PAGE gel containing 6 M urea. For peptide detection via 
fluorescence, gels were scanned using a Typhoon FLA 9500 FluorImager. 
 
HR reporter assay 
HR frequency was measured as described previously (28,29). Briefly, following 
siRNA transfection, 100'000 HeLa cells containing a stably integrated DR-GFP 
reporter construct were seeded into 12-well plates. The day after, cells were either 
mock-transfected or transfected with 0.6 μg I-SceI expression plasmid (pCBASce) 
using jetPrime transfection reagent (Polyplus transfection). 4 hours later medium was 
exchanged and either a one-hour peptide incubation or second siRNA transfection 
was performed. Peptide incubations were repeated 24 and 34 hours post-I-SceI 
transfection. After each peptide incubation, 0.5 ml of DMEM + 20% FCS was 
directly added to the peptide/DMEM mix. 48 hours after I-SceI transfection, cells 
were harvested and directly analyzed for GFP expression by flow cytometry using an 
Attune Nxt Flow Cytometer. 
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Immunofluorescence microscopy 
24 hours post-siRNA transfection, 80'000 cells were seeded on coverslips in 24-well 
plates. The day after, cells were treated either with 100 nM CPT for 1 hour or 
irradiated and incubated for another hour with the peptides, before releasing them for 
3 hours by directly adding 1 ml of DMEM + 14% FCS. Alternatively, cells were 
transfected with the peptides, followed by 1-hour CPT treatment and direct 
processing. Cells were pre-extracted for 5 minutes on ice (25 mM HEPES pH 7.4, 50 
mM NaCl, 1 mM EDTA, 3 mM MgCl2, 300 mM sucrose, 0.5% Triton X-100), fixed 
with 4% formaldeyhde (w/v) in PBS for 15 minutes at room temperature, before 
incubating them with indicated primary and appropriate secondary antibodies for 1 
hour. Afterwards, coverslips were mounted with Vectashield (Vector Laboratories) 
containing DAPI and sealed. Images were acquired on Leica DMI6000 widefield 
fluorescence microscope with a 63x objective. 
 
DNA fiber analysis 
DNA fiber analyses were carried out as described previously (30). In brief, U2OS 
cells were seeded into 6-well plates at a confluence of 40%. 24 hours later, cells were 
pulse-labeled with 33 μM CIdU for 30 minutes, followed by 340 μM IdU for 30 
minutes prior to incubation with 2 mM HU and peptides (10 μM) for 4 hours in 
serum-free medium. Cells were lysed (200 mM Tris-HCl pH 7.4, 50 mM EDTA, 
0.5% SDS) and DNA fibers were stretched onto glass slides before fixation in 
Methanol-Acetic acid (3:1, Merck) overnight. Rehydration in PBS was followed by 
denaturation in 2.5 M HCl for 1 hour, a PBS wash and blockage (2% BSA (w/v) PBS, 
0.1% Tween 20) for 40 minutes. CIdU and IdU staining was performed using anti-
BrdU primary and secondary antibodies for 2.5 hours. Coverslips were mounted using 
on May 23, 2018. © 2018 American Association for Cancer Research. mct.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on April 13, 2018; DOI: 10.1158/1535-7163.MCT-17-1156 
? 13 
Antifade Gold (Invitrogen). Images were acquired on Olympus microscope IX81 with 
60x magnification and analysis was carried out using ImageJ software. 
 
Colony-formation assay 
Indicated cell lines were plated in poly-L-lysine (Sigma-Aldrich) coated 24-well 
plates at low cell dilutions of 200 cells/well in technical triplicates. PEO1 and PEO4 
cells were seeded at 500 and 1000 cells/well, respectively. 24 hours later, cells were 
washed once with PBS and incubated with olaparib in presence or absence of 
peptides. After 1 hour, 1 ml of appropriate medium containing 14% FCS with 
indicated olaparib concentrations was directly added to the cells without removing the 
peptide solution. For MCF10A cells, FCS concentration of culture medium was 
increased to 7%. Alternatively, HeLa cells were treated for 1 hour with 1 μM CPT, 
washed twice with PBS and peptide transfection was carried out for 1 hour before 
directly adding 1 ml of DMEM + 14% FCS. Cells were grown for 10 days before 
fixation with crystal violet solution (0.5 % crystal violet, 20% ethanol (w/v)). For 
analysis, plates were scanned and analyzed with the ImageJ Plugin ColonyArea using 
the parameter Colony Intensity, integrating the percentage of the covered area and 
staining intensity (31).  
 
Statistical analysis 
All results were confirmed in at least two independent experiments. Quantitative data 
are displayed as mean ± s.d. and statistical analyses were performed using GraphPad 
Prism 7. P values < 0.05 were considered significant. 
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Results  
BRC4 peptide inhibits BRCA2-RAD51 interaction. 
It is well established that BRCA2 binds RAD51 through its BRC repeats composed of 
two highly conserved tetrameric motifs (Supplementary Fig. S1A). Among the eight 
BRC repeats, BRC4 was reported to display the highest affinity for RAD51, mainly 
using its FHTA sequence to bind the RAD51 oligomerization motif. To specifically 
target the BRCA2-RAD51 protein interaction interface, we therefore synthesized a 
16-mer peptide mimicking the N-terminal half of BRC4 comprising the FHTA 
hydrophobic motif (Fig. 1A). In addition to the 'wild type' BRC4 peptide (BRC4wt), 
we included a 'mutated' BRC4 peptide (BRC4mut) harboring an inverted FHTA 
sequence (Fig. 1A). Employing N-terminally biotinylated peptides, recombinant 
RAD51 was efficiently pulled down by BRC4wt but to a much lesser extent by 
BRC4mut (Fig. 1B). In agreement with previous reports (32), we observed that GST-
tagged BRCA2 fusion proteins spanning BRC 1-2, BRC 3-5 or the C-terminal (C-
term) domain were able to interact with RAD51 (Supplementary Fig. S1B and Fig. 
1C). Remarkably, BRC4wt was able to outcompete each of these individual 
interactions in a concentration-dependent manner (Fig. 1D). Interestingly, the BRC4 
peptide was more effective in outcompeting RAD51 binding to the BRCA2 C-term 
and BRC repeats 1-2 than to BRC repeats 3-5 (Fig. 1D), indicating that the BRC4 
repeat of BRCA2 exhibits the highest binding affinity for RAD51. Similar GST pull-
down results were obtained using HeLa nuclear extracts as a source for RAD51 
(Supplementary Fig. S1C). Given that the BRCA2 C-terminal region exclusively 
binds to assembled RAD51 oligomers, we reasoned that the BRC4 peptide is able to 
disrupt RAD51 multimers present in solution, which is in agreement with binding of 
the FHTA cluster to the RAD51 oligomerization motif (9,10,14). Most importantly, 
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co-immunoprecipitation experiments in U2OS cells inducibly expressing GFP-tagged 
RAD51 demonstrated that BRC4wt, but not BRC4mut, is capable of interfering both 
with BRCA2 binding to RAD51 and RAD51 oligomerization (Fig. 1E and 
Supplementary Figs. S1D and S1E). Taken together, our results indicated that a short, 
synthetic BRC4-derived peptide is proficient in blocking BRCA2-RAD51 protein-
protein interaction. 
 
The cell-penetrating peptide R9 facilitates intracellular delivery of BRC4. 
Native peptides do not readily cross cell membranes. To enhance cellular uptake, we 
decided to conjugate BRC4 peptides with a nona-arginine (R9) cell-penetrating 
peptide (CPP). Additionally, a red fluorescent dye (TAMRA) was N-terminally 
attached to R9-BRC4 peptides to analyze cellular uptake. Using confocal microscopy, 
we observed robust cytoplasmic and nuclear TAMRA signals in HeLa and U2OS 
cells upon transfection with R9-fused peptides (Fig. 2A). Moreover, we found that the 
concentration threshold for efficient R9-BRC4 cell penetration was above 10 µM 
(Supplementary Fig. S2A). Flow cytometry analyses further confirmed that BRC4 
peptide delivery reached a transduction efficiency of almost 100% when fused to R9 
(Fig. 2B and Supplementary Fig. S2B). Importantly, when replacing the TAMRA 
label with a green fluorescent dye (Fluorescein), we observed very similar subcellular 
localization patterns and fluorescent intensities of the R9-BRC4 peptides 
(Supplementary Figs. S2C and S2D). As peptides are prone to proteolytic degradation 
upon cellular uptake, we next determined the amount of intact peptides being 
delivered to the cells. In order to differentiate between full-length and degraded 
peptides, whole-cell lysates of HeLa and U2OS cells incubated with fluorescently 
labeled peptides were subjected to SDS-PAGE designed for resolving very low 
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molecular weight protein species (27). Using this approach, we detected significant 
amounts of intact TAMRA- and Fluorescein-labeled R9-BRC4 peptides being 
effectively delivered to HeLa and U2OS cells (Fig. 2C and Supplementary Fig. S2E). 
Comparing the band intensity of TAMRA signals between 10 pmol of freshly 
solubilized peptides directly loaded onto the gel and those of peptide-transduced cell 
lysates, we calculated a delivery rate of approximately 107 peptides per cell, yielding 
an estimated intracellular peptide concentration of around 1-10 μM (Fig. 2C). 
Next, to more precisely determine the intracellular residence time and stability of our 
BRC4 CPPs, we modified a previously established method (33) and monitored the 
Fluorescein signal intensity in HeLa cells over a time course of 24 hours after peptide 
incubation. SDS-PAGE analysis revealed that BRC4wt as well as BRC4mut cargo 
peptides were gradually degraded with an approximate half-life of 2 hours (Fig. 3A). 
Strikingly, using the same experimental set up, flow cytometry analysis of 
Fluorescein-R9-BRC4wt indicated a rather heterogeneous degradation pattern, which 
was most pronounced after 8 hours with a large proportion of cells still showing 
moderate to high fluorescent intensities (Fig. 3B). 
Collectively, we concluded that intracellular uptake of R9-BRC4wt and R9-BRC4mut 
was efficient and comparable as determined by confocal microscopy, flow cytometry 
and SDS-PAGE analysis, thus providing a solid basis for further mechanistic 
investigations. 
 
BRC4 peptide specifically inhibits RAD51-mediated homologous recombination. 
Conditional overexpression of full-length BRC4 was previously shown to inhibit 
DNA damage-induced RAD51 foci formation in MCF7 (breast cancer) and chicken 
DT40 cells (12,34). Therefore, we wanted to investigate whether the 16-mer BRC4 
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peptide fused to R9 was able to mimic this phenotype, indicative of effective 
disruption of RAD51 binding to BRCA2. To this end, HeLa or U2OS cells were first 
incubated with our peptides and subsequently treated with the DNA topoisomerase I 
poison camptothecin (CPT) to induce replication-dependent DSBs. Importantly, we 
did not detect any significant change in CPT-induced ATM and CHK2 
phosphorylation as well as γH2AX foci formation upon peptide addition, indicating 
regular activation of apical DNA damage response kinases (Fig. 4A and 
Supplementary Figs. S3A and S3B). In contrast, CPT-induced RAD51 foci formation 
in both cell lines was specifically compromised in presence of BRC4wt but not 
BRC4mut CPPs (Figs. 4B and 4C and Supplementary Figs. S3C and S3D). In line with 
this observation, BRC4wt significantly suppressed RAD51 foci formation following 
ionizing radiation (Fig. 4D). Notably, intrinsic RAD51 protein stability was not 
affected by BRC4wt cellular uptake (Supplementary Fig. S3E). To directly examine 
the impact of BRC4 peptides on DSB repair by HR, we performed repair reporter 
assays (DR-GFP) in HeLa cells and observed a significant decrease in HR frequency 
upon repetitive BRC4wt transfections (Fig. 4E). Throughout all experiments reported 
in this section, we observed that siRNA-mediated BRCA2 depletion conferred much 
stronger phenotypes compared to delivery of the BRC4wt peptide.  
In summary, our findings suggested that delivery of a synthetic BRC4 peptide 
potently inhibits RAD51 foci formation and HR, most likely as a result of defective 
BRCA2-mediated RAD51 loading onto resected DSBs. 
 
BRC4 peptide causes MRE11-dependent degradation of stalled replication forks. 
BRCA2-dependent RAD51 loading is not only critical for HR, but has also been 
established to protect stalled replication forks from nucleolytic degradation by 
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MRE11 (35,36). Thus, we examined a potential effect of the BRC4 peptide on 
replication fork protection by performing dual-labeling DNA fiber assays in the 
presence of hydroxyurea (HU), which stalls fork progression. Strikingly, we found 
that the BRC4wt CPP resulted in shortening of nascent DNA tracts, indicative of 
increased fork degradation (Fig. 5A). BRC4 intracellular uptake did not interfere with 
global replication rates, as we could not observe any differences in EdU incorporation 
(Supplementary Fig. S4). Similar to what has been shown for BRCA2-deficient cells, 
fork degradation in BRC4 peptide-transduced cells was completely rescued both by 
mirin, an MRE11 small molecule inhibitor (Fig. 5B), and by siRNA-mediated 
MRE11 depletion (Fig. 5C). Of note, BRC4 delivery did not result in additive or 
synergistic effects when delivered into BRCA2-depleted cells, indicating that peptide-
mediated fork degradation resulted most likely from specific targeting of the BRCA2-
RAD51 interaction (Fig. 5C). 
 
BRC4 peptide confers hypersensitivity to PARP inhibition in cancer cell lines. 
Based on our molecular analyses providing robust evidence of the inhibitory effect of 
the BRC4 peptide on BRCA2 functions in HR and fork protection, we next sought to 
determine if it also sensitizes cells to DNA-damaging agents. Profound 
hypersensitivity of BRCA2 mutant cells to poly(ADP-ribose) polymerase (PARP) 
inhibitors has become an emerging therapeutic paradigm known as synthetic lethality 
(37). Therefore, we performed clonogenic survival assays in peptide-transfected HeLa 
cells treated with the PARP inhibitor olaparib (38). Indeed, targeting of the BRCA2-
RAD51 interaction by BRC4wt CPPs resulted in a significant reduction in cellular 
viability in response to chronic PARP inhibition (Figs. 6A and 6B). Consistent with 
impaired RAD51 foci formation, delivery of BRC4wt CPPs also sensitized HeLa cells 
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to CPT (Supplementary Fig. S5A). Upon treatment with olaparib, we estimated the 
IC50 value of BRC4 to be around 10 µM for HeLa cells (Fig. 6C). Importantly, R9-
BRC4wt alone did not decrease cell survival in otherwise undamaged cells (Fig. 6C). 
Moreover, despite its relatively short half-life, the efficacy of BRC4 CPPs in 
sensitizing HeLa cells to PARP inhibition was comparable to that of the B02 small-
molecule compound, which specifically inhibits RAD51 binding to DNA (23,39) 
(Fig. 6D). To further exclude potential off-target effects of the BRC4 CPP in 
stimulating olaparib-induced cytotoxicity, we employed PEO1 (BRCA2 null) and 
PEO4 (BRCA2 revertant to wild-type) isogenic ovarian cancer cell lines (40). 
Notably, we observed a strong synergy between PARP inhibition and R9-BRC4 
peptides in PEO4 cells, whereas PEO1 cells did not exhibit BRC4-mediated 
sensitivity towards olaparib (Supplementary Fig. S5B). Differential peptide uptake 
could be excluded as both cell lines displayed comparable uptake efficiency and 
intracellular peptide localization (Supplementary Fig. S5B). Finally, in addition to 
HeLa cells, we observed that BRC4 CPPs elicited olaparib-induced cell death of 
U2OS human osteosarcoma cells but not of non-cancerous cell lines, including 
hTERT-immortalized human retinal pigment epithelial cells (hTERT-RPE1), SV40-
immortalized human fetal lung fibroblasts (MRC5) and human breast epithelial cells 
(MCF10A) (Fig. 6E and Supplementary Fig. S6A). This finding could at least in part 
be explained by an overall low cellular uptake efficiency and predominant endosome 
trapping of BRC4 peptides in RPE1, MRC5 and MCF10A non-tumorigenic cell lines 
(Supplementary Figs. S6B and S6C). 
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Discussion  
PPIs represent attractive but at the same time challenging targets for pharmacological 
intervention in cancer therapy. The emergence of successful peptide-based PPI 
inhibitors seemed promising, yet drug development was faced with the low membrane 
translocation ability of native peptides. The identification of a wide range of carrier 
molecules, commonly termed as CPPs or protein transduction domains, provided a 
possible solution for this major limitation (19). 
Here, we designed a 16-amino acid short peptide derived from the N-terminal half of 
the human BRCA2 BRC4 repeat able to occupy the RAD51 oligomerization interface 
and thereby potently inhibiting the interaction between BRCA2 and RAD51. Covalent 
fusion of the BRC4 peptide with the cationic polyarginine R9 CPP resulted in 
efficient uptake into both cytoplasm and nucleus, causing defects in HR repair, 
increased fork degradation, and, ultimately, hypersensitivity to DNA-damaging 
agents.  
Detailed biochemical studies have demonstrated that the full-length BRC4 repeat 
covering both FHTA and LFDE tetrameric cluster motifs selectively interacts with 
RAD51 and inhibits RAD51-DNA complex formation (15,41). In order to increase 
the likelihood of intracellular peptide uptake (42), we reduced the length of the native 
BRC4 peptide sequence from 35 to 16 amino acids, including only the first FHTA 
module, which was shown to mimic the RAD51 oligomerization motif (14). In line 
with our findings, a similar 17-mer N-terminal BRC4 peptide was reported to 
compete with full-length BRC4 for RAD51 binding, albeit with modest potency (15). 
We further corroborated the importance of the FHTA sequence by showing that 
BRC4 16-mer peptides harboring a mirrored ATHF sequence display greatly reduced 
RAD51 binding affinity. 
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Importantly, intracellular BRC4 peptide uptake in the low micromolar range was 
sufficient to impair BRCA2-RAD51 complex formation. A high uptake efficiency 
was likely achieved through a combination of the potent CPP R9 with the beneficial 
biochemical properties of the BRC4 peptide, including its positive net charge, 
hydrophobicity, and three-dimensional conformation (18). CPP internalization 
involves both endocytosis and direct translocation, whereby direct cell penetration is 
preferred because endocytosis can lead to the trapping of peptides in endosomes and 
their ultimate degradation (18). Multiple factors, including the CPP, cargo identity, 
concentration, cell type and differentiation status, influence the balance between both 
uptake mechanisms (18). We primarily observed a diffuse fluorescent staining and 
only minor punctuate patterns, indicative of direct translocation as the preferred 
uptake mechanism. The substantial number of peptide molecules reaching the 
intracellular space might compensate for the short half-life. Even though only 5% of 
intact peptides are present 24 hours after transfection, the absolute peptide number per 
cell at this stage still adds up to 106 functional peptides. According to a recent 
proteomics study in the U2OS cell line, most proteins involved in DSB repair 
processes including BRCA2 were shown to be of low to moderate abundance (102-104 
copies per cell) (43). Based on these numbers, we speculated that BRC4 peptides are 
present in high molar excess over their endogenous BRCA2 target protein even 24 
hours after uptake. 
RAD51 and its property to self-assemble are under dynamic control to enable faithful 
homology-directed DSB repair. Yu et al. proposed the presence of three RAD51 
fractions in the cell: a mobile fraction of RAD51 monomers, an immobile 
oligomerized fraction, and an immobile BRCA2-bound fraction (44). Strikingly, they 
found the BRCA2-bound fraction to be selectively mobilized upon DNA damage and 
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suggested a dual BRCA2 function of RAD51 sequestration and mobilization. 
Importantly, the other fractions did not change, suggesting that only the BRCA2-
bound RAD51 fraction is involved in DNA repair. Notably, R9-BRC4wt did not affect 
viability under unstressed growth conditions of conventionally cultured cancer cell 
lines. Thus, we hypothesize that under normal, undamaged conditions, RAD51 is 
stably bound to BRCA2 and the peptide's affinity for RAD51 is not high enough to 
disassemble the protein complex. Accordingly, the BRC4 mimetic peptide is only 
able to disassemble mobilized BRCA2-RAD51 complexes. We speculate that upon 
mobilization and ultimate RAD51 loading onto ssDNA, the protein complex becomes 
increasingly unstable due to an equilibrium change during DNA loading. In this 
context, the peptide is potent enough to sequester RAD51 transiently dissociated from 
BRCA2. We further presume that at low levels of DNA damage, requiring only a 
small fraction of BRCA2-bound RAD51, repair processes are not significantly 
disturbed by the BRC4 peptide. However, upon increasing DNA damage load and 
replication stress, when there is a high demand of functional BRCA2-RAD51 
complexes, a major pool of RAD51 is sequestered away from BRCA2 by the BRC4 
peptide. 
Despite its potentially rather high dissociation constant compared to SMIs, BRC4 
peptides provided an unexpectedly high degree of specificity. CPPs have often been 
reported to cause unspecific membrane disruption, which has led to false conclusions 
regarding their specificity for a number of peptide therapeutics. Since we do not 
observe a decrease in cell viability upon BRC4 peptide uptake, we can exclude such 
unspecific CPP-mediated toxicity (45). Furthermore, our finding that MRE11 
depletion fully rescued the peptide-induced replication fork degradation phenotype 
and the lack of synergy between peptides and PARP inhibition in BRCA2-deficient 
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cancer cells argue against potential off-target activity of the BRC4 CPP. Nevertheless, 
when comparing the outcomes of siRNA-mediated BRCA2 depletion versus R9-
BRC4wt peptide delivery, depletion is commonly yielding much more pronounced 
phenotypes. A possible explanation for this relates to the high susceptibility of 
peptides to extra- and intracellular protease attacks (17). To improve their 
pharmacokinetic potential, possible peptide optimizations include various backbone 
modifications and cyclization (17,46). Moreover, the BRCA2-RAD51 interaction 
might not be completely abolished by the BRC4 peptide as it only comprises the first 
FHTA but lacks the second LFDE tetrameric cluster motif. 
The lack of cell-type specificity is commonly reported to present another major 
limitation of CPP-mediated drug delivery (19,20). Strikingly, we could not find a 
synergistic relationship between the PARP inhibitor olaparib and the R9-BRC4 
peptide in normal cell lines as compared to cancer cell lines. Interestingly, our peptide 
uptake data suggest an overall decreased intracellular BRC4 concentration. It is 
reasonable to speculate that efficient intracellular peptide delivery relies on specific 
membrane components or lipid compositions that are more uptake responsive in 
cancer versus non-cancerous cell lines. Numerous reports classify lipid metabolic 
reprogramming as a major source of cell transformation (47). Specifically, the 
sphingolipid metabolism, which was suggested to influence R9-mediated peptide 
uptake, was reported to significantly alter during transformation (48). Additionally, 
cancer cells possess a more negatively charged membrane than normal cells, which is 
partly caused by a loss in membrane symmetry and the exposure of anionic 
phosphatidylcholine on the outer leaflet (49). This feature, in combination with higher 
membrane fluidity (50), might favor the uptake of the cationic R9-BRC4 peptide. 
Ultimately, the BRC4 peptide could emerge as a potent radio- and chemosensitizer. 
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Specifically, BRC4 peptide-induced HR-deficiency could represent a promising 
strategy for expanding the utility of PARP inhibitors, successfully applied in breast 
and ovarian cancer patients with a germline BRCA1 or BRCA2 mutation (51,52), to 
BRCA-proficient cancers. Similarly, the BRC4 peptide could re-sensitize BRCA1/2-
mutated tumors that acquired chemoresistance to PARP inhibitors by restoring HR 
(53). Moreover, malignant cells are frequently compromised in genome stability 
maintenance pathways that are synthetically lethal with HR deficiency (54). 
Consequently, monotherapy with the identified BRCA2 peptide inhibitor could 
provide a promising option for the treatment of these tumors. The BRCA2-BRC4 
peptide described in this study could also be applied in combination with proton 
irradiation, which was shown to be highly advantageous over conventional photon 
therapy. Notably, it was found that HR-deficient tumor cells exhibit an enhanced 
susceptibility towards proton- versus photon irradiation (55). Drug-induced HR-
deficiency with the BRC4 peptide inhibitor could make this advantageous effect 
accessible for patients with HR-proficient tumors. Lastly, we reveal a straightforward 
approach to study distinct PPIs in a biological context without the need of elaborate 
mutagenesis methodologies and provide a potent research tool to study BRCA2-
dependent RAD51 loading to ssDNA in different biological contexts. 
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Figure Legends 
Figure 1. A short BRC4 peptide inhibits BRCA2-RAD51 interaction. 
A, Amino acid sequences of BRCA2-derived 16-mer peptides used in this study. In 
addition to the wild type BRC4 peptide (BRC4wt), a mutant version (BRC4mut) was 
included, characterized by an inverted FHTA tetrapeptide motif. B, Biotinylated 
BRC4 peptides coupled to streptavidin beads were used to perform pull-down assays 
using bacterially expressed and purified human RAD51. Inputs and pulled-down 
protein complexes were analyzed by immunoblotting. SE and LE denote short and 
long exposure times of the same anti-RAD51 immunoblot. C, Different GST-BRCA2 
fusion proteins coupled to glutathione-sepharose beads were used to perform pull-
down assays using recombinant RAD51. Inputs and pulled-down protein complexes 
were analyzed by immunoblotting. D, GST-BRCA2 pull-down assays with 
recombinant RAD51 in the absence or presence of increasing amounts of BRC4wt 
peptides. Inputs and pulled-down protein complexes were analyzed by 
immunoblotting. E, Lysates of U2OS cells inducibly expressing GFP-RAD51 were 
supplemented with 50 µg of the indicated BRC4 peptides and subjected to 
immunoprecipitation (IP) using anti-GFP affinity resin. Inputs and co-
immunoprecipitated protein complexes were analyzed by immunoblotting. 
 
Figure 2. The cell-penetrating peptide nona-arginine (R9) mediates efficient 
delivery of BRC4 peptides into human cells. 
A, HeLa and U2OS cells were stained for 30 minutes with Hoechst 33342 to visualize 
nuclei and washed with PBS before adding 10 µM of the indicated TAMRA-labeled 
peptides. After 1-hour incubation in serum-free medium, cells were washed 
thoroughly to remove any membrane-bound peptides and live cells were directly 
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imaged on a confocal microscope. Gains were adjusted for each condition to reduce 
background fluorescence and to visualize strong and weak signals at the same time. 
The scale bar represents 20 μm. B, HeLa and U2OS cells were transfected with 10 
µM of the indicated TAMRA-labeled peptides in serum-free medium for 1 hour. Cells 
were harvested by trypsinization and TAMRA signal intensities were recorded on a 
flow cytometer by scoring 20'000 events. Bar graph depicts median TAMRA 
fluorescence intensity. a.u. = arbitrary units. Data are presented as the mean ± s.d. (n 
= 3). C, HeLa and U2OS cells were incubated with 10 μM of the indicated TAMRA-
labeled peptides. After 1 hour, cells were harvested by trypsinization. 10 pmol of 
freshly solubilized peptides (lanes 2-5) and whole-cell lysates of 70'000 peptide-
transfected cells (lanes 6-15) were loaded onto Tricine SDS-PAGE gel and TAMRA 
signals were visualized using a FluoroImager. 
 
Figure 3. R9-BRC4 peptides have an approximate half-life of 2-4 hours upon cell 
entry. 
A, HeLa cells were transfected with 10 μM of the indicated Fluorescein-labeled 
peptides in serum-free DMEM for 1 hour, followed by a release in serum-containing 
medium for the indicated time points. Left panel, 10 pmol of freshly solubilized 
peptides (lane 2) and whole-cell lysates of peptide-transduced cells (lanes 3-7) were 
loaded onto Tricine SDS-PAGE gel and Fluorescein signals were analyzed using a 
FluoroImager. Right panel, quantification of relative Fluorescein signal intensities of 
intact full-length R9-BRC4wt and R9-BRC4mut peptides. Data are represented as mean 
± s.d. (n = 4). B, HeLa cells incubated with Fluorescein-R9-BRCwt peptides as in (A) 
were analyzed by flow cytometry recording 20'000 events for each condition. The 
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intensity of the Fluorescein signal is plotted against the side-scatter area (SSC-A). 
Gates display percentages of cells showing moderate to high fluorescent intensities. 
 
Figure 4. BRC4 peptide inhibits RAD51 foci formation and homologous 
recombination. 
A, HeLa cells were either transfected with control (CNTL) or BRCA2 siRNA oligos 
for 48 hours, or incubated with 10 µM of the indicated cell-penetrating peptides 
(CPPs) for 1 hour before treatment with 100 nM camptothecin (CPT) for 1 hour. 
Whole-cell lysates were analyzed by immunoblotting using the indicated antibodies. 
B and C, Same cells as in (A) were treated with 100 nM CPT for 1 hour before 
transfecting them with the depicted peptides (10 µM) for 1 hour and releasing them 
for 3 hours in serum-containing medium. Cells were pre-extracted, fixed, and 
immunostained for RAD51. (B) Scale bars represent 10 μm and 5 µm (Zoom). (C) 
The graph illustrates the percentage of cells displaying more than 10 RAD51 
foci/nucleus. For each condition at least 100 cells were scored. D, Same cells as in 
(A) were irradiated with increasing doses of IR, peptide-transfected (10 µM) and 
released for 3 hours in serum-containing medium prior to pre-extraction, fixation, and 
immunostaining for RAD51. The graph illustrates the percentage of cells displaying 
more than 10 RAD51 foci/nucleus. For each condition at least 100 cells were scored. 
E, HeLa DR-GFP cells were transfected with the I-SceI expression plasmid 48 hours 
post-siRNA transfection. Alternatively, one-hour incubation periods with 10 μM 
peptides took place 4 hours, 24 hours and 34 hours post-I-SceI transfection of HeLa 
DR-GFP cells. A second siRNA transfection was performed 24 hours after I-SceI 
transfection. Cells were harvested 48 hours post-I-SceI transfection and GFP-positive 
cells were scored by flow cytometry. 20'000 events were recorded. The graph 
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illustrates the percentage of GFP-positive cells as a read-out for HR efficiency. Data 
in C, D and E display the mean ± s.d. (n ≥ 3). Statistical significance (***, p-value ≤ 
0.001; ns, non significant) was calculated with Tukey's multiple comparison test using 
two-way ANOVA (C and D) and one-way ANOVA (E). 
 
Figure 5. BRC4 peptide provokes MRE11-dependent degradation of stalled DNA 
replication forks. 
A, U2OS cells were transfected with indicated siRNA oligos for 48 hours or left 
untransfected. Subsequently, cells were labeled with CIdU and IdU before adding 
hydroxyurea (HU) together with indicated peptides (10 μM) in serum-free medium 
for 4 hours followed by DNA fiber spreading. Upper panel shows the experimental 
set up, representative DNA fiber images and their corresponding IdU/CIdU ratios, 
respectively. Lower panel shows IdU/CIdU ratios for each condition illustrated by a 
dot plot with mean ratios denoted as a red line. B, Same cells as in (A) were 
additionally treated with the MRE11 inhibitor mirin.  C, U2OS cells were transfected 
with the indicated siRNA oligos for 48 hours before dual labeling and HU treatment 
in combination with 10 μM R9 or R9-BRC4wt peptides. Representative immunblot is 
shown to indicate individual knockdown efficiencies. Approximately 250 DNA 
replication tracks were scored and numbers indicate the mean ± s.d. (n = 2). Statistical 
differences (****, p-value ≤ 0.0001; ns, non significant) were determined by Mann-
Whitney U test. 
 
Figure 6. BRC4 peptide sensitizes cancer cells to PARP inhibition. 
A, HeLa cells were transfected with the indicated siRNAs or left untransfected for 
standard peptide transduction. 24 hours later, cells were plated at low cell density into 
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24-well plates. Another 24 hours later, non-siRNA transfected cells were incubated 
for 1 hour with 10 μM of peptides in serum-free medium supplemented with 1 μM 
olaparib. Finally, serum-containing medium supplemented with 1 μM olaparib was 
added, cells were grown for 10 days and colonies were stained using crystal violet. 
Representative images of a colony formation assay are shown. Clonogenic survival 
was determined by quantifying the colony intensity of olaparib-treated relative to 
untreated and is depicted as bar graph. Data are represented as mean ± s.d. (n = 4). 
Statistical significance (***, p-value ≤ 0.001; ns, non significant) was calculated with 
Tukey's multiple comparison test using one-way ANOVA. B, Peptide-transfected 
HeLa cells as in (A) were treated with increasing concentrations of olaparib and 
survival was determined by colony formation assay. C, Same cells as in (A) were 
treated with 1 µM olaparib in combination with increasing concentrations of BRC4 
peptides and survival was determined by colony formation assay. D, Same cells as in 
(B) were treated with 10 μM of the RAD51 inhibitor BO2 under identical 
experimental conditions as used for the BRC4 peptide and survival was determined 
by colony formation assay. Data in B-D are represented as mean ± s.d. (n ≤ 3). E, 
HeLa, U2OS, RPE1, MRC5 and MCF10A were identically treated as in (A) and 
survival was determined by colony formation assay. Left panel, knockdown 
efficiencies were analyzed by immunoblotting of whole-cell lysates of indicated cell 
lines. Right panel, relative clonogenic survival is depicted as mean ± s.d. (n = 4). 
Statistical significance (****, p-value ≤ 0.0001; **, p-value ≤ 0.01; ns, non 
significant) was calculated with Tukey's multiple comparison test using one-way 
ANOVA. 
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